A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder.

Abstract:

:This UK multicenter, noncomparative, open-trial study assessed risperidone in 74 first-psychotic-episode patients (DSM-IV schizophrenia) treated with flexible doses. Treatment commenced at 1 mg/day, increasing to 2 mg after 3 days; then adjusted to 8 mg/day maximum. Treatment duration was 12 weeks (Phase 1) with follow-up of 62 patients to 1 year on risperidone or another antipsychotic (Phase 2). Superiority over baseline was recorded on all Positive and Negative Syndrome Scale (PANSS) subscale scores at week 12 (P < 0.0001), occurring after 3 days of treatment. Clinical Global Impression of Severity of Illness and Improvement (CGI-Severity) significantly improved over Phase 1 (80% of patients improved, 1% deteriorated). Treatment was considered from being very to quite acceptable in 79% and a success in 77% (P = 0.0001). Only 5 patients switched to another antipsychotic. Significant improvements were maintained to 1 year. Treatment-related adverse events reported by > 10% of patients in Phase 1 were somnolence (23%) and fatigue (10.8%). Five patients stopped risperidone due to adverse events. Nine patients reported that adverse events started in Phase 2, and 3 patients stopped risperidone. Twenty-one patients (28%) in Phase 1 and 4 patients (6%) in Phase 2 (including a patient taking thioridazine) reported extrapyramidal symptoms (EPS); none stopped treatment. There was no significant change in Abnormal Involuntary Movement Scale (AIMS) or Targeting Abnormal Kinetic Effects (TAKE) scale at 12 weeks. No significant change in AIMS and a significant improvement in TAKE scale were found from week 12 to 1 year. There was no significant difference in efficacy and tolerability between 1- to 4-mg/day and 5- to 8-mg/day dose groups in Phase 1 or 2. Low-dose risperidone is concluded to be effective and well tolerated in first episode psychosis. Only 2 patients (3%) required doses of over 6 mg/day.

journal_name

J Clin Psychopharmacol

authors

Huq ZU,RIS-GBR-32 Investigators.

doi

10.1097/01.jcp.0000115663.45074.8a

subject

Has Abstract

pub_date

2004-04-01 00:00:00

pages

220-4

issue

2

eissn

0271-0749

issn

1533-712X

journal_volume

24

pub_type

临床试验,杂志文章,多中心研究
  • Concomitant use of acetylcholine esterase inhibitors and urinary antispasmodics among Finnish community-dwelling persons with Alzheimer disease.

    abstract::Concomitant use of acetylcholine esterase inhibitors (AChEIs) and anticholinergic drugs, such as urinary antispasmodics (UA), is generally considered as inappropriate because of their opposite pharmacological actions. However, prevalence and the duration or factors associated with concomitant use have not been previou...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000218

    authors: Torvinen-Kiiskinen S,Taipale H,Tanskanen A,Tiihonen J,Hartikainen S

    更新日期:2014-12-01 00:00:00

  • Novel antipsychotics and severe hyperlipidemia.

    abstract::Newer atypical antipsychotics demonstrate superior effectiveness, with a diminished incidence of extrapyramidal side effects compared with older typical antipsychotics, but they have been associated with the development of obesity and new-onset diabetes. A small number of reports documenting modest hypertriglyceridemi...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-200108000-00003

    authors: Meyer JM

    更新日期:2001-08-01 00:00:00

  • Methamphetamine self-administration in humans during D-amphetamine maintenance.

    abstract::Agonist replacement may be a viable treatment approach for managing stimulant use disorders. This study sought to determine the effects of D-amphetamine maintenance on methamphetamine self-administration in stimulant using human participants. We predicted that D-amphetamine maintenance would reduce methamphetamine sel...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000207

    authors: Pike E,Stoops WW,Hays LR,Glaser PE,Rush CR

    更新日期:2014-12-01 00:00:00

  • The young adult chronic patient: population overview.

    abstract::Uninstitutionalized young adults with chronic mental disorders and social disabilities pose a new challenge in community psychiatry. These attention-seeking, help-rejecting young men and women spend most of their lives in the community and differ markedly from older deinstitutionalized chronic psychiatric patients. Ma...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Pepper B

    更新日期:1985-06-01 00:00:00

  • Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer's disease.

    abstract::Previous studies with functional magnetic resonance imaging (fMRI) demonstrated a differential brain activity and connectivity after treatment with donepezil in Alzheimer's disease (AD) when compared to healthy elders. Importantly however, there are no available studies where the placebo or control group included comp...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0b013e3182825bfd

    authors: Solé-Padullés C,Bartrés-Faz D,Lladó A,Bosch B,Peña-Gómez C,Castellví M,Rami L,Bargalló N,Sánchez-Valle R,Molinuevo JL

    更新日期:2013-04-01 00:00:00

  • A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.

    abstract::The current study aimed at establishing the prevalence of impulse control disorders (ICDs) in patients with Parkinson disease (PD) and their association with demographic, drug-related, and disease-related characteristics. We performed a single-center cross-sectional study of 805 PD patients. Impulse control disorders ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3182979830

    authors: Poletti M,Logi C,Lucetti C,Del Dotto P,Baldacci F,Vergallo A,Ulivi M,Del Sarto S,Rossi G,Ceravolo R,Bonuccelli U

    更新日期:2013-10-01 00:00:00

  • Effects of intravenous metoclopramide in 81 patients with tardive dyskinesia.

    abstract::We compared acute effects of single intravenous administrations of metoclopramide (40 mg) and placebo in a double-blind crossover study involving 81 patients with tardive dyskinesia. Metoclopramide produced significantly greater reduction in mean total Abnormal Involuntary Movement Scale score as well as in ratings fo...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Doongaji DR,Jeste DV,Jape NM,Sheth AS,Apte JS,Vahia VN,Desai AB,Parikh MD,Rathi LG,Ghandi MH,Parikh RM,Thatte S,Bharadwaj J

    更新日期:1982-12-01 00:00:00

  • Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population.

    abstract::Weight gain is a problem commonly encountered with antipsychotic treatment and has become more apparent with increasing use of the newer atypical antipsychotics. The adipocyte-derived hormone, leptin, has been associated with body weight and energy homeostasis, and abnormal regulation of leptin could play a role in we...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/jcp.0b013e3180582412

    authors: Zhang XY,Tan YL,Zhou DF,Haile CN,Cao LY,Xu Q,Shen Y,Kosten TA,Kosten TR

    更新日期:2007-06-01 00:00:00

  • The impact of acamprosate on cue reactivity in alcohol dependent individuals: a functional magnetic resonance imaging study.

    abstract::Alcohol cue-induced brain activation has been studied extensively in alcoholics. However, little is known about the impact of standard treatment protocols on this phenomenon. The current study aimed at investigating the impact of the anticraving substance acamprosate on alcohol cue-related brain activity. Patients und...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e318267b586

    authors: Langosch JM,Spiegelhalder K,Jahnke K,Feige B,Regen W,Kiemen A,Hennig J,Olbrich HM

    更新日期:2012-10-01 00:00:00

  • Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study.

    abstract::This paper examines the relationship between plasma concentration of antidepressant and both clinical response and adverse effects in treatment-resistant depressed adolescents. Adolescents (n = 334) with major depression who had not responded to a selective serotonin reuptake inhibitor (SSRI) were randomized to 1 of 4...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/JCP.0b013e318204b117

    authors: Sakolsky DJ,Perel JM,Emslie GJ,Clarke GN,Wagner KD,Vitiello B,Keller MB,Birmaher B,Asarnow JR,Ryan ND,McCracken JT,Strober MJ,Iyengar S,Porta G,Brent DA

    更新日期:2011-02-01 00:00:00

  • Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived?

    abstract::In a double-blind, parallel groups study, 60 healthy student volunteers (29 men and 31 women, aged 19-22 years) were randomly allocated to receive placebo, 100 or 200 mg modafinil. Two hours later, in the early evening, they completed an extensive cognitive battery. The 3 groups did not differ in self-ratings of sleep...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000155816.21467.25

    authors: Randall DC,Viswanath A,Bharania P,Elsabagh SM,Hartley DE,Shneerson JM,File SE

    更新日期:2005-04-01 00:00:00

  • Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder.

    abstract::Twenty-one women with generalized anxiety disorder (GAD) participated in a 6-week, double-blind, placebo-controlled trial to assess the treatment and abrupt withdrawal effects of diazepam on psychic and somatic symptoms of anxiety. The results confirmed those of previous studies reporting that (1) clinical doses of di...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-199606000-00002

    authors: Pourmotabbed T,Mcleod DR,Hoehn-Saric R,Hipsley P,Greenblatt DJ

    更新日期:1996-06-01 00:00:00

  • Effects of Intranasal Oxytocin Administration on Sexual Functions in Healthy Women: A Laboratory Paradigm.

    abstract:PURPOSE:The neuropeptide oxytocin (OXT) has a variety of physiological functions in maternal behavior and attachment including sexual behavior. Based on animal research and our previous human studies, we set out to investigate intranasal administration of OXT and hypothesized that OXT should be able to modulate sexual ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0000000000000863

    authors: Kruger THC,Deiter F,Zhang Y,Jung S,Schippert C,Kahl KG,Heinrichs M,Schedlowski M,Hartmann U

    更新日期:2018-06-01 00:00:00

  • Psychological strategies for discontinuing benzodiazepine treatment.

    abstract::Successful discontinuation of therapeutic drugs requires patients to negotiate two potentially difficult phases. First, they must complete the drug discontinuation procedure itself, which may entail coping with rebound and withdrawal symptoms as well as anxiety due to stopping a treatment on which they depend psycholo...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004714-199912002-00004

    authors: Spiegel DA

    更新日期:1999-12-01 00:00:00

  • Platelet monoamine oxidase response to lithium treatment in psychiatric patients.

    abstract::Platelet monoamine oxidase (MAO) activity was studied in bipolar and schizophrenic patients treated with lithium and was found to be increased as a nonspecific drug effect. Greater MAO increase in manic patients was correlated with lesser clinical improvement. There was no correlation of MAO activity with short-term o...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Huang LG,Bowden CL

    更新日期:1984-12-01 00:00:00

  • Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.

    abstract::Idazoxan, a selective alpha 2-adrenergic antagonist, was added to stable doses of fluphenazine treatment in six patients with schizophrenia who participated in a double-blind, placebo-controlled pharmacologic study. Compared with fluphenazine alone, combining idazoxan (mean dose, 120 mg/day) with fluphenazine (mean do...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Litman RE,Hong WW,Weissman EM,Su TP,Potter WZ,Pickar D

    更新日期:1993-08-01 00:00:00

  • Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression.

    abstract::On the basis of a previous report suggesting the effectiveness of the beta-adrenoceptor/5-HT1A antagonist pindolol to accelerate the antidepressant effect of a selective serotonin reuptake inhibitor (SSRI) and to produce a therapeutic effect in drug-resistant depressed patients, these open studies were undertaken to f...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-199506000-00011

    authors: Blier P,Bergeron R

    更新日期:1995-06-01 00:00:00

  • Influence of olanzapine on QT variability and complexity measures of heart rate in patients with schizophrenia.

    abstract::Previous studies have shown that untreated patients with acute schizophrenia present with reduced heart rate variability and complexity as well as increased QT variability. This autonomic dysregulation might contribute to increased cardiac morbidity and mortality in these patients. However, the additional effects of n...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31818a6d25

    authors: Bär KJ,Koschke M,Berger S,Schulz S,Tancer M,Voss A,Yeragani VK

    更新日期:2008-12-01 00:00:00

  • Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment.

    abstract::This study investigated the effects of antidepressant treatment on platelet activation in depressed patients with ischemic heart disease (IHD). Plasma levels of platelet alpha-granule release products beta-thromboglobulin (BTG) and platelet factor 4 (PF4) were measured in 17 depressed patients with IHD who were treate...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200004000-00004

    authors: Pollock BG,Laghrissi-Thode F,Wagner WR

    更新日期:2000-04-01 00:00:00

  • Carbamazepine-induced increases in total serum cholesterol: clinical and theoretical implications.

    abstract::To assess the effect of carbamazepine (CBZ) upon total serum cholesterol, we examined 38 inpatients with affective illness and one with multiple personality disorder who received a course of CBZ monotherapy. CBZ therapy yielded significant increases in total serum cholesterol that became evident during the second week...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Brown DW,Ketter TA,Crumlish J,Post RM

    更新日期:1992-12-01 00:00:00

  • Prolactin and Estrogen Levels in Postmenopausal Women Receiving Aripiprazole Augmentation Treatment for Depression.

    abstract:BACKGROUND:Antipsychotic drugs are well established to alter serum prolactin levels, often resulting in adverse effects including amenorrhea, galactorrhea, osteoporosis, and loss of libido. There is growing preclinical evidence that prolactin-elevating drugs can instigate the progression of precancerous lesions to brea...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000001335

    authors: Rahman T,Patrick C,Ma C,Nicol GE,Reynolds CF 3rd,Mulsant BH,Hartz SM,Yingling M,Lenze EJ

    更新日期:2021-01-01 00:00:00

  • Inhibition of CYP2D6 activity by bupropion.

    abstract::The purpose of this study was to assess the effect of bupropion on cytochrome P450 2D6 (CYP2D6) activity. Twenty-one subjects completed this repeated-measures study in which dextromethorphan (30-mg oral dose) was administered to smokers at baseline and after 17 days of treatment with either bupropion sustained-release...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000162805.46453.e3

    authors: Kotlyar M,Brauer LH,Tracy TS,Hatsukami DK,Harris J,Bronars CA,Adson DE

    更新日期:2005-06-01 00:00:00

  • The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study.

    abstract::Trichotillomania (TTM) is characterized by repetitive hair pulling resulting in hair loss. Data on the pharmacological treatment of TTM are limited. This study examined the opioid antagonist, naltrexone, in adults with TTM who had urges to pull their hair. Fifty-one individuals with TTM were randomized to naltrexone o...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0000000000000037

    authors: Grant JE,Odlaug BL,Schreiber LR,Kim SW

    更新日期:2014-02-01 00:00:00

  • Movement Disorders in Adults With Intellectual Disability and Behavioral Problems Associated With Use of Antipsychotics.

    abstract:BACKGROUND:Antipsychotic drugs are prescribed to approximately 30% to 40% of adults with intellectual disability (ID) and behavioral problems despite lack of evidence of effectiveness and potential adverse effects, including movement disorders. AIMS:The aim of this study was to examine the prevalence of movement disor...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000528

    authors: Scheifes A,Walraven S,Stolker JJ,Nijman HL,Tenback DE,Egberts TC,Heerdink ER

    更新日期:2016-08-01 00:00:00

  • Clozapine reduces water-drinking behavior in schizophrenic patients with polydipsia.

    abstract::Disordered water balance, or polydipsia, is an underassessed and underreported phenomenon present in the severely psychiatrically disabled population. Prevalence rates for polydipsia range from 6.2 to 20%. We followed up five male patients (mean age 43) with chronic schizophrenia who met the Kane criteria for being tr...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199608000-00010

    authors: Fuller MA,Jurjus G,Kwon K,Konicki PE,Jaskiw GE

    更新日期:1996-08-01 00:00:00

  • Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin.

    abstract::The therapeutic spectrum of nemonapride, a new substituted benzamide, and its relationship with plasma concentrations of the drug and prolactin were investigated by a fixed-dose study (18 mg/day for 3 weeks) in 31 patients with acutely exacerbated schizophrenia. Of 31 patients, 25 (80.6%) were responders who showed a ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004714-200008000-00003

    authors: Kondo T,Mihara K,Yasui N,Nagashima U,Ono S,Kaneko S,Ohkubo T,Osanai T,Sugawara K,Otani K

    更新日期:2000-08-01 00:00:00

  • Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects.

    abstract::We examined kinetic and dynamic factors to determine the pharmacological and behavioral safety and tolerability of low versus high doses of an opiate antagonist, naltrexone (50 mg/day vs. 100 mg/day), and acamprosate (2 g/day vs. 3 g/day), a functional N-methyl-D-aspartate receptor antagonist, both independently and c...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000084029.22282.bb

    authors: Johnson BA,O'Malley SS,Ciraulo DA,Roache JD,Chambers RA,Sarid-Segal O,Couper D

    更新日期:2003-06-01 00:00:00

  • Pharmacokinetics of benzodiazepines and psychostimulants in children.

    abstract::The pharmacokinetics of benzodiazepines and psychostimulants are reviewed and an overview of the kinetic principles relevant to the utilization of these drugs in infancy and childhood is provided. Newborns and premature infants can metabolize and eliminate diazepam, although the parent drug has a longer half-life and ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Coffey B,Shader RI,Greenblatt DJ

    更新日期:1983-08-01 00:00:00

  • Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm.

    abstract::This article reports the effects of imipramine on heart rate and blood pressure in panic disorder patients who participated in an 8-week double-blind dosage response treatment protocol. At the end of a placebo baseline, patients were randomly assigned to placebo or one of three weight-adjusted imipramine dosages: low ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: de Groot CM,Mavissakalian MR

    更新日期:1994-04-01 00:00:00

  • Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline.

    abstract:PURPOSE:This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50 and 100 mg versus placebo across age groups and severity of depression at baseline in patients with major depressive disorder. METHODS:Data from placebo and desvenlafaxine 50-mg and 100-mg dose arms were pooled from 9 short-term...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0000000000000674

    authors: Mosca D,Zhang M,Prieto R,Boucher M

    更新日期:2017-04-01 00:00:00